Home Newsfeeds Raymond James Maintains Outperform on Ameris, Lowers Price Target to $48

Raymond James Maintains Outperform on Ameris, Lowers Price Target to $48

Raymond James maintains Ameris (NASDAQ:ABCB) with a Outperform and lowers the price target from $50 to $48.

byBenzinga Newsdesk

July 7, 2022

1 minute read

Raymond James maintains Ameris (NASDAQ:ABCB) with a Outperform and lowers the price target from $50 to $48.

This Pot Giant Rebrands Popular Brand, Launches 50mg THC Edibles

By Vuk Zdinjak

July 10, 9:02 AM

Curaleaf Holdings, Inc. (OTCQX: CURLF) (CSE:CURA) unveiled the strategic national rebrand of its Select cannabis lifestyle brand across 15 U.S. states.

CSE:CURA

News

Bakkt Holdings Gives Update On Risk Factor Related To Going Concern; Mentions Substantial Doubt About The Co’s Ability To Continue For The Next 12 Months Without Raising Capital

By Benzinga Newsdesk

February 14, 1:50 PM

Liquidity and Going ConcernThe accompanying unaudited Consolidated Financial Statements are prepared in accordance with U.S. GAAP applicable to a going concern. This presentation contemplates the realization of assets

BKKT

Cue Biopharma Presents Updated Data From Phase 1 Trial of CUE-101 In Recurrent/Metastatic HPV+ Head And Neck Cancer At ASCO 2024

By Benzinga Newsdesk

June 4, 8:10 AM

Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and

CUE

Alcoa Shares Surge On Solid Q2 Results

By Akanksha Bakshi

July 20, 4:51 PM

Alcoa Corp (NYSE:AA) reported second-quarter revenue growth of 28.6% year-over-year to $3.64 billion, beating the consensus of $3.56 billion. Adjusted…

Raymond James Maintains Outperform on Ameris, Lowers Price Target to $48

Related Posts

This Pot Giant Rebrands Popular Brand, Launches 50mg THC Edibles

Bakkt Holdings Gives Update On Risk Factor Related To Going Concern; Mentions Substantial Doubt About The Co’s Ability To Continue For The Next 12 Months Without Raising Capital

Cue Biopharma Presents Updated Data From Phase 1 Trial of CUE-101 In Recurrent/Metastatic HPV+ Head And Neck Cancer At ASCO 2024

Alcoa Shares Surge On Solid Q2 Results